ASCENTAGE PHARMA GROUP INTERNATIONAL(AAPG)Earnings, Financials & Key Ratios
AAPG•NASDAQ
$21.57
$6.62B mkt cap·Price updated May 6, 2026
AboutAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.Show more
- Revenue$981M+341.8%
- EBITDA-$277M+64.5%
- Net Income-$405M+56.2%
- EPS (Diluted)-1.34+89.8%
- Gross Margin97.03%+12.5%
- EBITDA Margin-28.2%+92.0%
- Operating Margin-37.7%+90.4%
- Net Margin-41.34%+90.1%
- ROE-235.17%+39.1%
- ROIC-36.9%+57.1%
- Debt/Equity6.09-76.1%
- Interest Coverage-5.74+36.9%
AAPG Key Insights
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 132.2%
✗Weaknesses
- ✗High debt to equity ratio of 6.1x
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AAPG Price & Volume
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) stock price & volume — 10-year historical chart
Loading chart...
AAPG Growth Metrics
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years132.25%
3 Years227.53%
TTM264.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM84.45%
Return on Capital
10 Years-35.3%
5 Years-41.77%
3 Years-37.23%
Last Year-24.51%
AAPG Recent Earnings
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (50%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
Mar 24, 2026EPS
$0.65
Est $0.83
+21.7%
Revenue
$49M
Est $44M
+11.5%
Q3 2025
Aug 20, 2025EPS
$0.96
Revenue
$33M
Q2 2025
Mar 27, 2025EPS
$1.00
Est $0.02
-6134.6%
Revenue
$21M
Q4 2024
Dec 31, 2024EPS
$0.25
Revenue
$21M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $0.65vs $0.83+21.7% | $49Mvs $44M+11.5% |
| Q3 2025 | Aug 20, 2025 | $0.96 | $33M |
| Q2 2025 | Mar 27, 2025 | $1.00vs $0.02-6134.6% | $21M |
| Q4 2024 | Dec 31, 2024 | $0.25 | $21M |
Based on last 12 quarters of dataView full earnings history →
AAPG Peer Comparison
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 BCAB | 5.38M | 4.57 | -0.09 | -81.82% | -29.8% | |||
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 GILD | 166.32B | 133.48 | 351.26 | 6.04% | 28.9% | 37.62% | 6.2% | 1.39 |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
 JAZZ | 13.32B | 212.26 | -36.35 | 4.88% | 0.66% | 0.71% | 9.74% | 1.26 |
Compare AAPG vs Peers
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AAPG Income Statement
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.67M | 6.33M | 6.81M | 14.51M | 12.45M | 27.91M | 209.71M | 221.98M | 980.65M | 1.29B |
| Revenue Growth % | - | -17.46% | 7.57% | 113.21% | -14.21% | 124.18% | 651.38% | 5.85% | 341.77% | 264.84% |
| Cost of Goods Sold | 261K | 0 | 0 | 2.1M | 1.97M | 3.33M | 22M | 30.54M | 29.09M | 63.13M |
| COGS % of Revenue | 3.4% | - | - | 14.44% | 15.79% | 11.92% | 10.49% | 13.76% | 2.97% | - |
| Gross Profit | 7.41M▲ 0% | 6.33M▼ 14.6% | 6.81M▲ 7.6% | 12.42M▲ 82.4% | 10.48M▼ 15.6% | 24.58M▲ 134.5% | 187.71M▲ 663.6% | 191.44M▲ 2.0% | 951.57M▲ 397.1% | 1.23B▲ 0% |
| Gross Margin % | 96.6% | 100% | 100% | 85.56% | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% | 95.12% |
| Gross Profit Growth % | - | -14.56% | 7.57% | 82.42% | -15.57% | 134.47% | 663.62% | 1.99% | 397.05% | - |
| Operating Expenses | 122.03M | 137M | 330.65M | 595.1M | 674.42M | 894.42M | 1.04B | 1.06B | 1.32B | 2.7B |
| OpEx % of Revenue | 1591.6% | 2164.92% | 4857.51% | 4100.48% | 5417.07% | 3204.65% | 494.74% | 479.35% | 134.74% | - |
| Selling, General & Admin | 17.71M | 13.4M | 89.72M | 98.85M | 64.06M | 191.26M | 328.02M | 376.46M | 383.12M | 822.4M |
| SG&A % of Revenue | 230.95% | 211.84% | 1318.01% | 681.13% | 514.52% | 685.28% | 156.41% | 169.59% | 39.07% | - |
| Research & Development | 102.69M | 118.81M | 249.56M | 463.88M | 564.57M | 766.49M | 743.1M | 706.97M | 947.25M | 1.87B |
| R&D % of Revenue | 1339.4% | 1877.61% | 3666.3% | 3196.33% | 4534.71% | 2746.3% | 354.35% | 318.48% | 96.59% | - |
| Other Operating Expenses | 1.63M | 4.78M | -8.63M | 32.37M | 45.8M | -63.34M | -33.6M | -19.36M | -9.07M | -2K |
| Operating Income | -114.62M▲ 0% | -130.67M▼ 14.0% | -50.25M▲ 61.5% | -582.68M▼ 1059.7% | -663.94M▼ 13.9% | -869.84M▼ 31.0% | -849.81M▲ 2.3% | -872.64M▼ 2.7% | -369.73M▲ 57.6% | -1.46B▲ 0% |
| Operating Margin % | -1495% | -2064.92% | -738.14% | -4014.92% | -5332.86% | -3116.57% | -405.23% | -393.11% | -37.7% | -113.24% |
| Operating Income Growth % | - | -14% | 61.55% | -1059.68% | -13.95% | -31.01% | 2.3% | -2.69% | 57.63% | - |
| EBITDA | -114.46M | -118.17M | -31.78M | -578.86M | -646.98M | -852.65M | -802.39M | -779.44M | -276.56M | -1.31B |
| EBITDA Margin % | -1492.86% | -1867.37% | -466.92% | -3988.56% | -5196.59% | -3055.01% | -382.62% | -351.12% | -28.2% | -100.92% |
| EBITDA Growth % | - | -3.24% | 73.1% | -1721.26% | -11.77% | -31.79% | 5.89% | 2.86% | 64.52% | 16.32% |
| D&A (Non-Cash Add-back) | 164.37K | 12.5M | 18.46M | 3.83M | 16.96M | 17.18M | 47.42M | 93.19M | 93.17M | 159.3M |
| EBIT | -104.58M | -62.18M | -46.85M | -1.48B | -669.19M | -815.52M | -834.39M | -836.8M | -330.8M | -1.46B |
| Net Interest Income | -3.25M | -57.63M | -29.86M | 8.63M | -1.04M | -9.63M | -43.06M | -63.65M | -26.61M | -43.28M |
| Interest Income | 13K | 304K | 7.06M | 12.91M | 5.22M | 7.11M | 9.73M | 32.41M | 37.84M | 5.04M |
| Interest Expense | 3.26M | 57.94M | 36.92M | 4.27M | 6.25M | 16.73M | 52.78M | 96.06M | 64.45M | 48.32M |
| Other Income/Expense | 6.78M | 10.55M | -23.07M | -899.63M | -11.51M | 37.59M | -37.36M | -60.23M | -25.52M | -48.97M |
| Pretax Income | -107.84M▲ 0% | -120.12M▼ 11.4% | -346.91M▼ 188.8% | -1.48B▼ 327.3% | -675.45M▲ 54.4% | -832.25M▼ 23.2% | -887.17M▼ 6.6% | -932.86M▼ 5.2% | -395.25M▲ 57.6% | -1.51B▲ 0% |
| Pretax Margin % | -1406.53% | -1898.17% | -5096.36% | -10213.71% | -5425.29% | -2981.9% | -423.05% | -420.24% | -40.31% | -117.02% |
| Income Tax | 0 | -1.6M | -1.6M | -1.6M | 2.16M | -49.83M | -4.25M | -7.15M | 10.43M | 6.04M |
| Effective Tax Rate % | 0% | 1.33% | 0.46% | 0.11% | -0.32% | 5.99% | 0.48% | 0.77% | -2.64% | -0.4% |
| Net Income | -107.84M▲ 0% | -118.51M▼ 9.9% | -345.31M▼ 191.4% | -1.48B▼ 328.8% | -677.61M▲ 54.2% | -782.42M▼ 15.5% | -882.92M▼ 12.8% | -925.64M▼ 4.8% | -405.43M▲ 56.2% | -1.52B▲ 0% |
| Net Margin % | -1406.53% | -1872.85% | -5072.82% | -10202.67% | -5442.62% | -2803.38% | -421.02% | -416.98% | -41.34% | -117.46% |
| Net Income Growth % | - | -9.9% | -191.36% | -328.81% | 54.24% | -15.47% | -12.84% | -4.84% | 56.2% | 9.36% |
| Net Income (Continuing) | -107.84M | -118.51M | -345.31M | -1.48B | -677.61M | -782.42M | -882.92M | -925.71M | -405.68M | -1.52B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.21M | 9.97M | 9.91M |
| EPS (Diluted) | -2.08▲ 0% | -2.29▼ 10.1% | -6.67▼ 191.3% | -28.01▼ 319.9% | -12.56▲ 55.2% | -12.28▲ 2.2% | -13.40▼ 9.1% | -13.12▲ 2.1% | -1.34▲ 89.8% | -4.45▲ 0% |
| EPS Growth % | - | -10.1% | -191.27% | -319.94% | 55.16% | 2.23% | -9.12% | 2.09% | 89.79% | 84.45% |
| EPS (Basic) | -2.08 | -2.29 | -6.67 | -28.01 | -12.56 | -12.28 | -13.40 | -13.12 | -1.34 | - |
| Diluted Shares Outstanding | 51.77M | 51.77M | 51.77M | 52.87M | 53.98M | 63.65M | 65.92M | 70.57M | 302.06M | 341.59M |
| Basic Shares Outstanding | 51.77M | 51.77M | 51.77M | 52.87M | 53.98M | 63.65M | 65.92M | 70.57M | 302.06M | 341.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AAPG Balance Sheet
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 463.7M | 414.71M | 990.22M | 909.11M | 1.08B | 1.89B | 1.64B | 1.34B | 1.47B | 1.91B |
| Cash & Short-Term Investments | 451.92M | 398.99M | 971.49M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B | 1.66B |
| Cash Only | 294.53M | 14.82M | 957.09M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B | 1.66B |
| Short-Term Investments | 157.39M | 384.17M | 14.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.31M | 7.85M | 5.25M | 2.53M | 480K | 54.13M | 61.49M | 163.54M | 99.07M | 78.36M |
| Days Sales Outstanding | 395.52 | 452.96 | 281.67 | 63.53 | 14.07 | 707.86 | 107.02 | 268.9 | 36.88 | 84.21 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.93M | 9.45M | 16.17M | 6.6M | 8.59M |
| Days Inventory Outstanding | - | - | - | - | - | 431.02 | 156.77 | 193.2 | 82.79 | 60.82 |
| Other Current Assets | 11.22K | 25.18K | 6.42M | 3.95M | 17.31M | 59.26M | 16.6M | 24.54M | 24.63M | 160.31M |
| Total Non-Current Assets | 129.64M | 166.95M | 239.16M | 295.94M | 652M | 1.05B | 1.19B | 1.16B | 1.14B | 1.14B |
| Property, Plant & Equipment | 4.51M | 25.33M | 33.99M | 110.22M | 477M | 854.3M | 650.02M | 957.23M | 905.86M | 871.96M |
| Fixed Asset Turnover | 1.70x | 0.25x | 0.20x | 0.13x | 0.03x | 0.03x | 0.32x | 0.23x | 1.08x | 1.41x |
| Goodwill | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M |
| Intangible Assets | 87.13M | 80.71M | 108.53M | 104.31M | 97.39M | 60.41M | 84.3M | 85.45M | 76M | 70.99M |
| Long-Term Investments | 1.91M | 0 | 0 | 4.62M | 31.77M | 27.84M | 18.53M | 18.95M | 33.86M | 123.35M |
| Other Non-Current Assets | 13.31M | 36.22M | 71.94M | 52.1M | 21.13M | 35.88M | 361.93M | 10.05M | 59M | 220.79M |
| Total Assets | 593.34M▲ 0% | 581.66M▼ 2.0% | 1.23B▲ 111.4% | 1.21B▼ 2.0% | 1.73B▲ 43.6% | 2.94B▲ 69.8% | 2.83B▼ 3.7% | 2.5B▼ 11.7% | 2.62B▲ 4.7% | 3.05B▲ 0% |
| Asset Turnover | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.07x | 0.09x | 0.37x | 0.46x |
| Asset Growth % | - | -1.97% | 111.36% | -1.98% | 43.65% | 69.84% | -3.73% | -11.65% | 4.7% | -2.44% |
| Total Current Liabilities | 77.62M | 79.53M | 105.27M | 202.06M | 276.15M | 361.11M | 881.15M | 934.17M | 1.17B | 1.24B |
| Accounts Payable | 156K | 3.82M | 5.08M | 13.08M | 23.36M | 70.86M | 95.56M | 72.44M | 91.97M | 118.68M |
| Days Payables Outstanding | 218.16 | - | - | 2.28K | 4.34K | 7.77K | 1.59K | 865.74 | 1.15K | 529.31 |
| Short-Term Debt | 0 | 0 | 35M | 85M | 44.75M | 39.8M | 510.31M | 606.65M | 769.62M | 822.61M |
| Deferred Revenue (Current) | 121.02K | 6.6K | 0 | 6.6K | 6.58K | 0 | 24.35M | 38.41M | 54.09M | 92.5M |
| Other Current Liabilities | 12.46M | 12.23M | 24.76M | 46.9M | 16.87M | 58.73M | 2.82M | 0 | 0 | 286.84M |
| Current Ratio | 5.97x | 5.21x | 9.41x | 4.50x | 3.91x | 5.22x | 1.86x | 1.44x | 1.26x | 1.26x |
| Quick Ratio | 5.97x | 5.21x | 9.41x | 4.50x | 3.91x | 5.21x | 1.85x | 1.42x | 1.26x | 1.26x |
| Cash Conversion Cycle | - | - | - | - | - | -6.63K | -1.32K | -403.64 | -1.03K | -384.28 |
| Total Non-Current Liabilities | 530.33M | 633.93M | 2.14B | 112.51M | 608.27M | 1.34B | 1.54B | 1.5B | 1.18B | 1.13B |
| Long-Term Debt | 0 | 0 | 0 | 0 | 473.06M | 1.03B | 1.27B | 1.17B | 868.64M | 867.11M |
| Capital Lease Obligations | 472K | 2.88M | 4.46M | 9.21M | 6.08M | 8.25M | 9.14M | 12.92M | 20.79M | 60.4M |
| Deferred Tax Liabilities | 21.76M | 20.16M | 18.56M | 16.96M | 15.36M | 13.75M | 12.15M | 10.55M | 5.37M | 21.77M |
| Other Non-Current Liabilities | 499.36M | 594.93M | 2.09B | 51.25M | 73.57M | 52.34M | 35.33M | 18.3M | 6.27M | 291.93M |
| Total Liabilities | 607.95M | 713.46M | 2.24B | 314.57M | 884.42M | 1.71B | 2.42B | 2.43B | 2.34B | 2.37B |
| Total Debt | 830K | 4.9M | 42.04M | 101.41M | 529.7M | 1.08B | 1.79B | 1.8B | 1.67B | 1.72B |
| Net Debt | -293.7M | -9.92M | -915.04M | -777.11M | -490.28M | -622.6M | 317.09M | 726.3M | 431.92M | 54.71M |
| Debt / Equity | - | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 25.42x | 6.09x | 6.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.31x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
| Interest Coverage | -35.17x | -2.26x | -1.36x | -136.33x | -106.15x | -51.99x | -16.10x | -9.08x | -5.74x | -30.31x |
| Total Equity | -14.61M▲ 0% | -131.8M▼ 802.3% | -1.01B▼ 667.5% | 890.48M▲ 188.0% | 846.62M▼ 4.9% | 1.23B▲ 45.8% | 408.66M▼ 66.9% | 70.63M▼ 82.7% | 274.16M▲ 288.2% | 675.91M▲ 0% |
| Equity Growth % | - | -802.35% | -667.53% | 188.03% | -4.92% | 45.84% | -66.9% | -82.72% | 288.16% | 221.86% |
| Book Value per Share | -0.28 | -2.55 | -19.54 | 16.84 | 15.68 | 19.40 | 6.20 | 1.00 | 0.91 | 1.98 |
| Total Shareholders' Equity | -14.61M | -131.8M | -1.01B | 890.48M | 846.62M | 1.23B | 408.66M | 60.42M | 264.19M | 666M |
| Common Stock | 0 | 0 | 63K | 142K | 154K | 178K | 180K | 197K | 214K | 239K |
| Retained Earnings | 0 | 0 | -615.82M | -2.1B | -2.77B | -3.56B | -4.44B | -5.37B | -5.77B | -6.36B |
| Treasury Stock | 0 | 0 | -4K | -574 | -4K | -470 | -26.55M | -21.35M | -8K | -2.96M |
| Accumulated OCI | 0 | 0 | 0 | 0 | -509.81M | -550.95M | -518.51M | -504.46M | -510.59M | -516.07M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.21M | 9.97M | 9.91M |
AAPG Cash Flow Statement
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -45.89M | -107.98M | -237.67M | -460.31M | -609.96M | -604.68M | -653.91M | -726.08M | -111.36M | -111.36M |
| Operating CF Margin % | -598.58% | -1706.46% | -3491.51% | -3171.67% | -4899.24% | -2166.53% | -311.82% | -327.09% | -11.36% | - |
| Operating CF Growth % | - | -135.3% | -120.09% | -93.68% | -32.51% | 0.87% | -8.14% | -11.04% | 84.66% | 262.4% |
| Net Income | -107.84M | -120.12M | -346.91M | -741.16M | -675.45M | -832.25M | -887.17M | -932.86M | -395.25M | -1.52B |
| Depreciation & Amortization | 164.37K | 12.5M | 18.46M | 3.83M | 27.42M | 28.33M | 62.91M | 93.19M | 93.17M | 140.79M |
| Stock-Based Compensation | 64.99M | 0 | 27.57M | 70.82M | 74.03M | 46.97M | 22.11M | 31.5M | 20.92M | 60.27M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -6.74M | -10.9M | 36.13M | 195.06M | 19.29M | 227.18M | 43.82M | 91.23M | 58.84M | 1.42B |
| Working Capital Changes | 2.15M | 10.53M | 27.08M | 11.14M | -55.25M | -74.91M | 104.41M | -9.15M | 110.97M | 18.35M |
| Change in Receivables | -301K | 556K | 0 | 0 | 0 | -53.97M | -388K | -91.54M | 62.75M | -28.79M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -3.93M | -5.52M | -6.72M | 9.57M | 2.85M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 24.7M | -23.11M | 19.52M | 0 |
| Cash from Investing | -152.61M | -230.35M | 292.81M | -201.33M | -107.37M | -466.52M | -384.61M | 21.92M | -362.04M | -275.34M |
| Capital Expenditures | -3.29M | -20.54M | -48.16M | -77.46M | -249.92M | -435.42M | -203.29M | -46.11M | -24.29M | -36.42M |
| CapEx % of Revenue | 42.85% | 324.53% | 707.58% | 533.7% | 2007.4% | 1560.07% | 96.94% | 20.77% | 2.48% | - |
| Acquisitions | 6.1M | 0 | -33.38M | 0 | 0 | -36.2M | -20M | -20M | -25.52M | -29.52M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -155.42M | -209.81M | -1.29M | -143.48M | -1.55M | -879K | -31.32M | 88.03M | -312.23M | -209.4M |
| Cash from Financing | 435.54M | 58.36M | 860.16M | 442.36M | 1.04B | 1.78B | 619.27M | 368.75M | 314.77M | 227.89M |
| Debt Issued (Net) | 0 | 0 | 35M | 50M | 432.81M | 548.59M | 695.87M | -13.36M | -145.34M | -98.85M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 1000K | -2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -25.87M | -26.78M | -5.92M | 0 | -7.88M |
| Other Financing | -581K | -2.53M | -85.45M | -39.92M | -27.02M | -41.97M | -49.83M | -82.05M | -73.83M | 334.62M |
| Net Change in Cash | 294.53M▲ 0% | -279.71M▼ 195.0% | 942.27M▲ 436.9% | -218.1M▼ 123.1% | 280.99M▲ 228.8% | 686.91M▲ 144.5% | -361.25M▼ 152.6% | -307.59M▲ 14.9% | -144.95M▲ 52.9% | 952.43M▲ 0% |
| Free Cash Flow | -49.26M▲ 0% | -128.52M▼ 160.9% | -287.13M▼ 123.4% | -541.72M▼ 88.7% | -861.43M▼ 59.0% | -1.04B▼ 20.9% | -890.88M▲ 14.4% | -782.92M▲ 12.1% | -135.65M▲ 82.7% | -505.39M▲ 0% |
| FCF Margin % | -642.55% | -2030.99% | -4218.11% | -3732.66% | -6919.13% | -3730.95% | -424.81% | -352.69% | -13.83% | -39.07% |
| FCF Growth % | - | -160.88% | -123.41% | -88.67% | -59.02% | -20.88% | 14.45% | 12.12% | 82.67% | 72.3% |
| FCF per Share | -0.95 | -2.48 | -5.55 | -10.25 | -15.96 | -16.36 | -13.52 | -11.09 | -0.45 | -0.45 |
| FCF Conversion (FCF/Net Income) | 0.43x | 0.91x | 0.69x | 0.31x | 0.90x | 0.77x | 0.74x | 0.78x | 0.27x | 0.33x |
| Interest Paid | 49K | 257K | 1.89M | 4.27M | 5.93M | 16.81M | 49.85M | 92.35M | 60.56M | 98.53M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AAPG Key Ratios
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -166.28% | -78.02% | -75.18% | -107.45% | -386.25% | -235.17% | -224.81% |
| Return on Invested Capital (ROIC) | - | - | -385.48% | -212.03% | -134.72% | -95.28% | -85.96% | -36.9% | -36.9% |
| Gross Margin | 100% | 100% | 85.56% | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% | 95.12% |
| Net Margin | -1872.85% | -5072.82% | -10202.67% | -5442.62% | -2803.38% | -421.02% | -416.98% | -41.34% | -117.46% |
| Debt / Equity | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 25.42x | 6.09x | 6.09x |
| Interest Coverage | -2.26x | -1.36x | -136.33x | -106.15x | -51.99x | -16.10x | -9.08x | -5.74x | -30.31x |
| FCF Conversion | 0.91x | 0.69x | 0.31x | 0.90x | 0.77x | 0.74x | 0.78x | 0.27x | 0.33x |
| Revenue Growth | -17.46% | 7.57% | 113.21% | -14.21% | 124.18% | 651.38% | 5.85% | 341.77% | 264.84% |
AAPG Frequently Asked Questions
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported $1.29B in revenue for fiscal year 2024. This represents a 16773% increase from $7.7M in 2016.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) grew revenue by 341.8% over the past year. This is strong growth.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported a net loss of $1.52B for fiscal year 2024.
Dividend & Returns
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) has a return on equity (ROE) of -235.2%. Negative ROE indicates the company is unprofitable.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) had negative free cash flow of $505.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates